[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623876":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":33,"centralContacts":38,"locations":43,"responsibleParty":73,"collaborators":75,"id":80,"slug":28,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":28,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":28,"studyType":92,"phases":93,"briefSummary":83,"conditions":95,"keywords":98,"overallStatus":100,"whyStopped":28,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Applied Biology, Inc.","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"DA-020 (0.1%)","EXPERIMENTAL","Topical Oxymetazoline 0.1% - 7mL",[13],"Drug: DA-020 (0.1%)",{"label":15,"type":10,"description":16,"interventionNames":17},"DA-020 (0.2%)","Topical Oxymetazoline 0.2% - 7mL",[18],"Drug: DA-020 (0.2%)",{"label":20,"type":10,"description":21,"interventionNames":22},"DA-020 (0.5%)","Topical Oxymetazoline 0.5% - 7mL",[23],"Drug: DA-020 (0.5%)",[25,29,31],{"type":26,"name":9,"description":9,"armGroupLabels":27,"otherNames":28},"DRUG",[9],null,{"type":26,"name":15,"description":15,"armGroupLabels":30,"otherNames":28},[15],{"type":26,"name":20,"description":20,"armGroupLabels":32,"otherNames":28},[20],[34],{"name":35,"affiliation":36,"role":37},"Andy Goren, MD","University of Rome G. Marconi","STUDY_DIRECTOR",[39],{"name":35,"role":40,"phone":41,"phoneExt":28,"email":42},"CONTACT","16507040850","clinicalstudies@appliedbiology.com",[44,62],{"facility":45,"status":28,"city":46,"state":28,"zip":28,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Hospital Samel","Manaus","Brazil",{"type":49,"coordinates":50},"Point",[51,52],-60.025,-3.10194,{"lat":52,"lon":51},[55,59],{"name":56,"role":40,"phone":57,"phoneExt":28,"email":58},"Daniel Fonseca, MD","+55 92 2129-2200","clinicalstudies@appliedbilogy.com",{"name":60,"role":61,"phone":28,"phoneExt":28,"email":28},"Daniel Foncseca, MD","PRINCIPAL_INVESTIGATOR",{"facility":63,"status":28,"city":64,"state":28,"zip":28,"country":65,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"University of Rome (\"G. Marconi\")","Rome","Italy",{"type":49,"coordinates":67},[68,69],12.51133,41.89193,{"lat":69,"lon":68},[72],{"name":35,"role":40,"phone":41,"phoneExt":28,"email":42},{"type":74,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[76,78],{"name":77,"class":6},"Daniel Alain, Inc.",{"name":79,"class":6},"Follea International Limited","100623876",false,"NCT07402330","Pharmacokinetic Study of DA-020","Inclusion Criteria:\n\n* Healthy females, age 18-55\n* BMI: 18-30 kg\u002Fm²\n* Fitzpatrick Skin Types I-IV (to standardize absorption risk)\n* Scalp free from irritation, dermatologic disease, or damage\n* Able to refrain from using other topical scalp products\n\nExclusion Criteria:\n\n* History of cardiovascular disease, hypertension, or arrhythmia\n* Scalp infections, wounds, or significant hair loss\n* Recent use of medications that interfere with CYP enzymes or adrenergic systems\n* Known sensitivity to phenylephrine or ethanol\n* Positive drug screen or abnormal ECG at screening",true,"FEMALE","18 Years","55 Years",{"count":90,"type":91},60,"ESTIMATED","INTERVENTIONAL",[94],"EARLY_PHASE1",[96,97],"Chemotherapy Induced Alopecia","Chemotherapy Side Effects",[96,99],"Chemotherapy Alopecia","NOT_YET_RECRUITING","2026-04-08",{"date":103,"type":104},"2026-04-13","ACTUAL",{"date":106,"type":91},"2026-04-16",{"date":108,"type":91},"2026-11-30",{"name":5,"class":6},2]